Patents by Inventor Quentin Florence

Quentin Florence has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-amyloid-beta antibodies
    Patent number: 11161898
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 2, 2021
    Assignee: rPeptide LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • Anti-tau antibodies
    Patent number: 10696739
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the tau protein. Such antibodies may be used for the modulation of tau activity and/or aggregation, to study the effects of the tau protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with neurodegenerative tauopathy.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: June 30, 2020
    Assignee: rPeptide, LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • ANTI-AMYLOID-BETA ANTIBODIES
    Publication number: 20200199210
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
    Type: Application
    Filed: November 8, 2019
    Publication date: June 25, 2020
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • Anti-amyloid-beta antibodies
    Patent number: 10494425
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: December 3, 2019
    Assignee: rPeptide, LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • ANTI-TAU ANTIBODIES
    Publication number: 20190211086
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the tau protein. Such antibodies may be used for the modulation of tau activity and/or aggregation, to study the effects of the tau protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with neurodegenerative tauopathy.
    Type: Application
    Filed: January 17, 2019
    Publication date: July 11, 2019
    Applicant: rPeptide LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • Anti-tau antibodies
    Patent number: 10202444
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the tau protein. Such antibodies may be used for the modulation of tau activity and/or aggregation, to study the effects of the tau protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with neurodegenerative tauopathy.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: February 12, 2019
    Assignee: rPeptide, LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • ANTI-AMYLOID-BETA ANTIBODIES
    Publication number: 20180051072
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 22, 2018
    Applicant: rPeptide LLC
    Inventors: Quentin FLORENCE, Nanda MENON, William MOFFITT, Bill LUNSFORD, III
  • ANTI-TAU ANTIBODIES
    Publication number: 20180051073
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the tau protein. Such antibodies may be used for the modulation of tau activity and/or aggregation, to study the effects of the tau protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with neurodegenerative tauopathy.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 22, 2018
    Applicant: rPeptide LLC
    Inventors: Quentin FLORENCE, Nanda MENON, William MOFFITT, Bill LUNSFORD, III
  • PURE FILAMENTOUS BACTERIOPHAGE AND METHODS OF PRODUCING SAME
    Publication number: 20160250266
    Abstract: The invention relates to compositions of purified filamentous bacteriophage, as well as methods that allow reproducible purification of high concentrations of filamentous bacteriophage.
    Type: Application
    Filed: December 10, 2015
    Publication date: September 1, 2016
    Inventors: Jason Wright, Antony Hitchcock, Frank Sugar, Tim Davies, Shreekant Adhikari, Nanda Menon, Quentin Florence
  • PURE FILAMENTOUS BACTERIOPHAGE AND METHODS OF PRODUCING SAME
    Publication number: 20130084337
    Abstract: The invention relates to compositions of purified filamentous bacteriophage, as well as methods that allow reproducible purification of high concentrations of filamentous bacteriophage.
    Type: Application
    Filed: August 3, 2012
    Publication date: April 4, 2013
    Applicant: NeuroPhage Pharmaceuticals, Inc.
    Inventors: Jason Wright, Antony Hitchcock, Frank Sugar, Tim Davies, Shreekant Adhikari, Nanda Menon, Quentin Florence